Zacks Research Issues Positive Estimate for Glaukos Earnings

Glaukos Co. (NYSE:GKOS - Free Report) - Analysts at Zacks Research boosted their Q4 2026 EPS estimates for Glaukos in a note issued to investors on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will earn $0.06 per share for the quarter, up from their prior estimate of $0.03. The consensus estimate for Glaukos' current full-year earnings is ($1.08) per share. Zacks Research also issued estimates for Glaukos' FY2027 earnings at $0.82 EPS.

Glaukos (NYSE:GKOS - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02). Glaukos had a negative return on equity of 16.53% and a negative net margin of 39.04%. The business had revenue of $105.50 million for the quarter, compared to the consensus estimate of $100.72 million.

A number of other analysts have also commented on GKOS. BTIG Research lifted their price target on shares of Glaukos from $140.00 to $149.00 and gave the stock a "buy" rating in a research note on Tuesday, November 26th. Stephens upgraded Glaukos to a "strong-buy" rating in a research note on Monday, December 2nd. Morgan Stanley lowered Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price objective for the company. in a report on Monday, December 2nd. Truist Financial increased their target price on Glaukos from $152.00 to $185.00 and gave the company a "buy" rating in a report on Wednesday, December 18th. Finally, Wells Fargo & Company upped their price target on shares of Glaukos from $153.00 to $160.00 and gave the company an "overweight" rating in a research report on Friday, February 21st. One investment analyst has rated the stock with a sell rating, one has given a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and a consensus target price of $163.25.

Remove Ads

Glaukos Stock Down 0.5 %

GKOS stock traded down $0.48 on Monday, reaching $100.76. 503,187 shares of the company traded hands, compared to its average volume of 582,757. The firm has a fifty day simple moving average of $137.56 and a 200-day simple moving average of $137.00. The company has a market cap of $5.70 billion, a P/E ratio of -35.21 and a beta of 0.99. Glaukos has a one year low of $85.31 and a one year high of $163.71. The company has a debt-to-equity ratio of 0.19, a current ratio of 5.54 and a quick ratio of 4.71.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 3,328 shares of the business's stock in a transaction on Friday, December 20th. The shares were sold at an average price of $149.85, for a total value of $498,700.80. Following the sale, the chief operating officer now owns 102,169 shares in the company, valued at $15,310,024.65. The trade was a 3.15 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 10,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total transaction of $1,502,800.00. Following the transaction, the director now directly owns 32,336 shares of the company's stock, valued at $4,859,454.08. This trade represents a 23.62 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 16,744 shares of company stock worth $2,504,131 over the last ninety days. Corporate insiders own 6.40% of the company's stock.

Hedge Funds Weigh In On Glaukos

Several institutional investors have recently bought and sold shares of GKOS. IFP Advisors Inc purchased a new stake in shares of Glaukos in the fourth quarter valued at $43,000. Asset Planning Inc purchased a new stake in shares of Glaukos in the 4th quarter worth $90,000. CoreCap Advisors LLC increased its position in Glaukos by 36.4% during the 4th quarter. CoreCap Advisors LLC now owns 750 shares of the medical instruments supplier's stock valued at $112,000 after purchasing an additional 200 shares during the period. Harvest Fund Management Co. Ltd lifted its holdings in Glaukos by 2,263.2% during the third quarter. Harvest Fund Management Co. Ltd now owns 898 shares of the medical instruments supplier's stock worth $117,000 after buying an additional 860 shares during the period. Finally, Picton Mahoney Asset Management bought a new stake in Glaukos during the fourth quarter valued at about $125,000. Institutional investors own 99.04% of the company's stock.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.